- The renoprotective effects of canagliflozin demonstrated in the CREDENCE study cannot yet be considered as an effect of the whole class of SGLT2 inhibitors2020 | Second Faculty of Medicine
- Výsledky studie CREDENCE: Canagliflozin prokázal snížení rizika selhání ledvin u diabetiků 2. typu s nefropatií2019 | Third Faculty of Medicine
- Léčba canagliflozinem snižuje riziko progrese renální insuficience a selhání ledvin u diabetiků 2. typu s nefropatií - výsledky studie CREDENCE2019 | Third Faculty of Medicine
- Canagliflozin reduces the risk of CKD progression in type 2 diabetes with nephropathy - main results of the CREDENCE study2019 | First Faculty of Medicine
- Diabetic kidney disease and new antidibetics2019 | Second Faculty of Medicine
- Renal-protective potential of new oral antidiabetics2015 | Third Faculty of Medicine